BioSpace News Archive

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held in Los Angeles on October 12-14, 2021 .

Phio Pharmaceuticals Corp. today announced two poster presentations at upcoming scientific conferences scheduled to take place in October 2021

Adaptive Phage Therapeutics, Inc. today announced that the Department of Defense (DoD) has awarded the company an additional $8 million for the continued development of bacteriophage therapies (PhageBankTM) for the treatment of infectious diseases.

September is Alzheimer’s awareness month, and Apollo Health is pleased to share their first publication, which demonstrates that a majority of participants experienced an improvement in cognition.

Inspirna, Inc. announced today its corporate name change from Rgenix to Inspirna and announced the appointment of Dieter Weinand to its Board of Directors, where he will serve as Chairman.

Disposable medical supplies consist of medical apparatuses, devices, or consumables used once or for a brief time in medical application.

Fact.MR – A Market Research and Competitive Intelligence Provider: A study published by Fact.MR pegs the global dental cements market to total US$ 1.2 billion by 2025.

Sunovion Pharmaceuticals Inc.,its parent company Sumitomo Dainippon Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614 and SEP-380135.

Electromedical Technologies, Inc . is pleased to announce that it has passed the ISO 13485:2016 recertification audit for Medical Device and Quality Management Systems.

Pfizer Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved CIBINQO®, an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older with inadequate response to existing therapies.